Pfizer Inc. (PFE)
| Market Cap | 139.32B |
| Revenue (ttm) | 63.83B |
| Net Income (ttm) | 10.75B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.89 |
| PE Ratio | 12.93 |
| Forward PE | 8.65 |
| Dividend | $1.72 (7.02%) |
| Ex-Dividend Date | Nov 7, 2025 |
| Volume | 8,900,817 |
| Open | 24.44 |
| Previous Close | 24.39 |
| Day's Range | 24.33 - 24.61 |
| 52-Week Range | 20.92 - 29.82 |
| Beta | 0.47 |
| Analysts | Hold |
| Price Target | 29.45 (+20.18%) |
| Earnings Date | Nov 4, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for PFE stock is "Hold." The 12-month stock price target is $29.45, which is an increase of 20.18% from the latest price.
News
Pfizer: Don't Forget About Value During AI Frenzy
Pfizer is rated a Strong Buy, offering a nearly 7% forward dividend yield, which is highly likely safe. PFE's revenue has stabilized, management is delivering cost savings, and a recent drug pricing d...
CEOs of Wells Fargo and Pfizer caution the U.S. could lose its edge to China without innovation
Wells Fargo CEO Charlie Scharf said AI is boosting productivity but will likely reduce workforce size. Pfizer CEO Albert Bourla warned China is closing the biotech and pharmaceutical patent gap rapidl...
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Pfizer CEO says US pharma industry needs to collaborate with China
Pfizer Chief Executive Albert Bourla said on Tuesday that the U.S. pharmaceutical industry needs to collaborate with China's, where speedy processes have vaulted it to 30% of global drug development o...
TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUK...
Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. D...
Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs
Fourteen of the highest-yielding, 'safer' S&P 500 dividend stocks are currently attractively priced, with free cash flow supporting their payouts. Top ten S&P 500 dividend 'dogs' are projected to deli...
Biotech Stocks Have Struggled Since 2021. Why They're Coming Back.
Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswin...
Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)
Pfizer's stock is poised for recovery, driven by recent corporate news and a three-year reprieve on drug-import tariffs from the Trump administration, strengthening the bullish case despite prior mark...
Pfizer Declares Fourth-Quarter 2025 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company's common stock, payable December 1, 2025, to...
Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $PFE #ADCs--Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman.
Pfizer Offers High Yield And Capital Appreciation Opportunities (Technical Analysis)
Pfizer surged 15% last week on positive news, including a direct-to-consumer deal and a three-year tariff reprieve. PFE offers a high 6.28% yield, with a forward PE of 8.87, and its dividend is consid...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Pfizer: TrumpRx Unlocks Opportunities With Drug Discounts
Pfizer delivered strong 2Q25 results with double-digit revenue growth, margin expansion, and robust earnings driven by Comirnaty, Paxlovid, and Vyndaqel. The TrumpRx deal offers discounted direct-to-c...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (Oct. 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
The Score: Pfizer, Tesla, Electronic Arts and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week's news
Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated
Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, e...
The drug price deal between Pfizer and the Trump administration was built on down-to-the-wire team negotiations, building on a relationship between CEO Albert Bourla and President Trump
Down-to-the wire team negotiations capped a long dance between President Trump and CEO Albert Bourla.
Pfizer: The Long Suffering Is Finally Over (Rating Upgrade)
Pfizer Inc. has secured an MFN pricing deal with the White House, easing recent tariff and drug repricing concerns while affording a win for Trump. PFE's solid dividend yield of >6% provides a robust ...
Heard on the Street: Pfizer's accord on price cuts with President Trump clears a cloud over the whole pharma industry
The company's accord with the president clears a cloud over the whole sector.
Why Pfizer's Trump Deal Is Good News for All of Big Pharma
The company's accord with the president clears a cloud over the whole sector.
Final Trade: GDX, PFE, GFS, BMY
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
Pfizer's Art Of The Deal
President Trump and Pfizer announced a deal to cut drug pricing yeseterday. And it looks like the pharmaceutical giant got the better end of it.
Stock Of The Day: Will Pfizer Head Higher?
Shares of Pfizer Inc. (NYSE:PFE) continue to head higher on Wednesday, a day after the company announced that it has secured a three-year grace period from President Donald Trump's tariffs on pharmace...